111 related articles for article (PubMed ID: 12556089)
1. Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer.
Contreras DN; Cobos E; Lox CD
Eur J Gynaecol Oncol; 2002; 23(6):491-5. PubMed ID: 12556089
[TBL] [Abstract][Full Text] [Related]
2. Is the circulating urokinase plasminogen activator upregulated by the circulating p105 fraction of the HER-2/neu proto-oncogene in patients with cervical cancer?
Contreras DN; Cobos E; Lox C
Clin Appl Thromb Hemost; 2004 Jul; 10(3):271-6. PubMed ID: 15247985
[TBL] [Abstract][Full Text] [Related]
3. Role and significance of HER-2/neu as a biomarker in the premalignant and malignant lesions of uterine cervix.
Varshney S; Maheshwari V; Aijaz M; Alam K
Ann Diagn Pathol; 2020 Apr; 45():151443. PubMed ID: 31923745
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of HER-2/neu oncogene in cervical cancer.
Ndubisi B; Sanz S; Lu L; Podczaski E; Benrubi G; Masood S
Ann Clin Lab Sci; 1997; 27(6):396-401. PubMed ID: 9433536
[TBL] [Abstract][Full Text] [Related]
5. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
6. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy.
Bellone S; Palmieri M; Gokden M; Joshua J; Roman JJ; Pecorelli S; Cannon MJ; Santin AD
Gynecol Oncol; 2003 Oct; 91(1):231-40. PubMed ID: 14529687
[TBL] [Abstract][Full Text] [Related]
7. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.
Kono K; Naganuma H; Sekikawa T; Amemiya H; Takahashi A; Iizuka H; Matsumoto Y
Tumour Biol; 2000; 21(3):139-44. PubMed ID: 10754464
[TBL] [Abstract][Full Text] [Related]
8. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
Tangjitgamol S; Ramirez PT; Sun CC; See HT; Jhingran A; Kavanagh JJ; Deavers MT
Int J Gynecol Cancer; 2005; 15(4):646-56. PubMed ID: 16014119
[TBL] [Abstract][Full Text] [Related]
10. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
Clin Chem; 2003 Oct; 49(10):1579-98. PubMed ID: 14500583
[TBL] [Abstract][Full Text] [Related]
11. Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck.
Hoffmann TK; Balló H; Braunstein S; Van Lierop A ; Wagenmann M; Bier H
Oral Oncol; 2001 Jan; 37(1):50-6. PubMed ID: 11120483
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
13. Circulating levels of HER-2/neu oncoprotein in breast cancer.
Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
[TBL] [Abstract][Full Text] [Related]
14. Serum HER-2/neu: a new predictive marker.
Voss A; Neumann R
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):584-5. PubMed ID: 12503824
[No Abstract] [Full Text] [Related]
15. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
16. Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
Krainer M; Brodowicz T; Zeillinger R; Wiltschke C; Scholten C; Seifert M; Kubista E; Zielinski CC
Oncology; 1997; 54(6):475-81. PubMed ID: 9394844
[TBL] [Abstract][Full Text] [Related]
17. Serum HER-2/neu in the management of breast cancer patients.
Lüftner D; Lüke C; Possinger K
Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
Shukla S; Singh BK; Pathania OP; Jain M
Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
[TBL] [Abstract][Full Text] [Related]
19. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
